Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Liabilities (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Total Liabilities readings, the most recent being $705.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 7.4% year-over-year to $705.1 million, compared with a TTM value of $705.1 million through Dec 2025, up 7.4%, and an annual FY2025 reading of $705.1 million, up 7.4% over the prior year.
  • Total Liabilities hit $705.1 million in Q4 2025 for Apellis Pharmaceuticals, up from $657.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $841.4 million in Q2 2021, with the low at $565.3 million in Q1 2024.
  • Median Total Liabilities over the past 5 years was $649.8 million (2024), compared with a mean of $644.4 million.
  • The sharpest move saw Total Liabilities skyrocketed 76.41% in 2021, then dropped 20.6% in 2022.
  • Year by year, Total Liabilities stood at $683.1 million in 2021, then fell by 13.58% to $590.3 million in 2022, then rose by 0.65% to $594.2 million in 2023, then increased by 10.49% to $656.5 million in 2024, then rose by 7.4% to $705.1 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $705.1 million, $657.6 million, and $665.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.